@prefix fhir: <http://hl7.org/fhir/> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

# - resource -------------------------------------------------------------------

<http://standardhealthrecord.org/fhir/CodeSystem/shr-oncology-BrcaReceptorStatusCS> a fhir:CodeSystem;
  fhir:nodeRole fhir:treeRoot;
  fhir:Resource.id [ fhir:value "shr-oncology-BrcaReceptorStatusCS"];
  fhir:DomainResource.text [
     fhir:Narrative.status [ fhir:value "generated" ];
     fhir:Narrative.div "<div xmlns=\"http://www.w3.org/1999/xhtml\">\n<p><b>SHR BrcaReceptorStatusCS CodeSystem</b></p>\n<p>Classification of receptor status in breast cancer.</p>\n</div>"
  ];
  fhir:CodeSystem.url [ fhir:value "http://standardhealthrecord.org/shr/oncology/cs/BrcaReceptorStatusCS"];
  fhir:CodeSystem.identifier [
     fhir:Identifier.system [ fhir:value "http://standardhealthrecord.org" ];
     fhir:Identifier.value [ fhir:value "shr.oncology.BrcaReceptorStatusCS" ]
  ];
  fhir:CodeSystem.version [ fhir:value "0.0.1"];
  fhir:CodeSystem.name [ fhir:value "SHR BrcaReceptorStatusCS CodeSystem"];
  fhir:CodeSystem.title [ fhir:value "SHR BrcaReceptorStatusCS CodeSystem"];
  fhir:CodeSystem.status [ fhir:value "draft"];
  fhir:CodeSystem.date [ fhir:value "2017-12-19"^^xsd:date];
  fhir:CodeSystem.publisher [ fhir:value "The MITRE Corporation: Standard Health Record Collaborative"];
  fhir:CodeSystem.contact [
     fhir:index 0;
     fhir:ContactDetail.telecom [
       fhir:index 0;
       fhir:ContactPoint.system [ fhir:value "url" ];
       fhir:ContactPoint.value [ fhir:value "http://standardhealthrecord.org" ]
     ]
  ];
  fhir:CodeSystem.description [ fhir:value "Classification of receptor status in breast cancer."];
  fhir:CodeSystem.caseSensitive [ fhir:value "true"^^xsd:boolean];
  fhir:CodeSystem.content [ fhir:value "complete"];
  fhir:CodeSystem.count [ fhir:value "4"^^xsd:nonNegativeInteger];
  fhir:CodeSystem.concept [
     fhir:index 0;
     fhir:CodeSystem.concept.code [ fhir:value "luminal_A" ];
     fhir:CodeSystem.concept.display [ fhir:value "Group 1. Includes tumors that are ER positive and PR positive, but negative for HER2. Luminal A breast cancers are likely to benefit from hormone therapy and may also benefit from chemotherapy." ];
     fhir:CodeSystem.concept.definition [ fhir:value "Group 1. Includes tumors that are ER positive and PR positive, but negative for HER2. Luminal A breast cancers are likely to benefit from hormone therapy and may also benefit from chemotherapy." ]
  ], [
     fhir:index 1;
     fhir:CodeSystem.concept.code [ fhir:value "luminal_B" ];
     fhir:CodeSystem.concept.display [ fhir:value "Group 2. Includes tumors that are ER positive, PR negative and HER2 positive. Luminal B breast cancers are likely to benefit from chemotherapy and may benefit from hormone therapy and treatment targeted to HER2." ];
     fhir:CodeSystem.concept.definition [ fhir:value "Group 2. Includes tumors that are ER positive, PR negative and HER2 positive. Luminal B breast cancers are likely to benefit from chemotherapy and may benefit from hormone therapy and treatment targeted to HER2." ]
  ], [
     fhir:index 2;
     fhir:CodeSystem.concept.code [ fhir:value "HER2_positive" ];
     fhir:CodeSystem.concept.display [ fhir:value "Group 3. Includes tumors that are ER negative and PR negative, but HER2 positive. HER2 breast cancers are likely to benefit from chemotherapy and treatment targeted to HER2." ];
     fhir:CodeSystem.concept.definition [ fhir:value "Group 3. Includes tumors that are ER negative and PR negative, but HER2 positive. HER2 breast cancers are likely to benefit from chemotherapy and treatment targeted to HER2." ]
  ], [
     fhir:index 3;
     fhir:CodeSystem.concept.code [ fhir:value "Triple_negative" ];
     fhir:CodeSystem.concept.display [ fhir:value "Group 4. Also called basal-like breast cancer, includes tumors that are ER negative, PR negative and HER2 negative. Basal-like breast cancers are likely to benefit from chemotherapy." ];
     fhir:CodeSystem.concept.definition [ fhir:value "Group 4. Also called basal-like breast cancer, includes tumors that are ER negative, PR negative and HER2 negative. Basal-like breast cancers are likely to benefit from chemotherapy." ]
  ] .

# - ontology header ------------------------------------------------------------

<http://standardhealthrecord.org/fhir/CodeSystem/shr-oncology-BrcaReceptorStatusCS.ttl> a owl:Ontology;
  owl:imports fhir:fhir.ttl .

# -------------------------------------------------------------------------------------

